[go: up one dir, main page]

DK1641438T3 - Fremgangsmåde til fremstilling af den amorfe form af et lægemiddel - Google Patents

Fremgangsmåde til fremstilling af den amorfe form af et lægemiddel

Info

Publication number
DK1641438T3
DK1641438T3 DK05758626.5T DK05758626T DK1641438T3 DK 1641438 T3 DK1641438 T3 DK 1641438T3 DK 05758626 T DK05758626 T DK 05758626T DK 1641438 T3 DK1641438 T3 DK 1641438T3
Authority
DK
Denmark
Prior art keywords
amorphous form
drug
preparing
preparation
active pharmaceutical
Prior art date
Application number
DK05758626.5T
Other languages
English (en)
Inventor
Claude Singer
Valerie Niddam-Hildesheim
Greta Sterimbaum
Szabolcs Szoke
Csaba Szabo
Lorant Gyuricza
Original Assignee
Teva Gyogyszergyar Zartkoeruen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Gyogyszergyar Zartkoeruen filed Critical Teva Gyogyszergyar Zartkoeruen
Application granted granted Critical
Publication of DK1641438T3 publication Critical patent/DK1641438T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18Halogen atoms or nitro radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • FMECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26DRYING
    • F26BDRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B11/00Machines or apparatus for drying solid materials or objects with movement which is non-progressive
    • F26B11/12Machines or apparatus for drying solid materials or objects with movement which is non-progressive in stationary drums or other mainly-closed receptacles with moving stirring devices
    • FMECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26DRYING
    • F26BDRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B5/00Drying solid materials or objects by processes not involving the application of heat
    • F26B5/04Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
    • F26B5/041Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum for drying flowable materials, e.g. suspensions, bulk goods, in a continuous operation, e.g. with locks or other air tight arrangements for charging/discharging

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mechanical Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DK05758626.5T 2004-06-01 2005-06-01 Fremgangsmåde til fremstilling af den amorfe form af et lægemiddel DK1641438T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57621604P 2004-06-01 2004-06-01
US58377804P 2004-06-28 2004-06-28
US59970004P 2004-08-05 2004-08-05
PCT/US2005/019485 WO2005117837A1 (en) 2004-06-01 2005-06-01 Process for preparation of amorphous form of a drug

Publications (1)

Publication Number Publication Date
DK1641438T3 true DK1641438T3 (da) 2010-06-07

Family

ID=35134738

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05758626.5T DK1641438T3 (da) 2004-06-01 2005-06-01 Fremgangsmåde til fremstilling af den amorfe form af et lægemiddel

Country Status (11)

Country Link
US (1) US7589128B2 (da)
JP (1) JP2008500405A (da)
KR (1) KR20060123772A (da)
AT (1) ATE458476T1 (da)
CA (1) CA2560984A1 (da)
DE (1) DE602005019509D1 (da)
DK (1) DK1641438T3 (da)
ES (1) ES2339682T3 (da)
IL (1) IL179719A0 (da)
MX (1) MXPA06010084A (da)
WO (1) WO2005117837A1 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060083784A1 (en) * 2002-08-07 2006-04-20 Smithkline Beecham Corporation Amorphous pharmaceutical compositions
KR20080112424A (ko) 2004-10-15 2008-12-24 테바 파마슈티컬 인더스트리즈 리미티드 텔미사르탄의 제조 방법
MX2007005348A (es) * 2004-11-03 2007-06-25 Teva Pharma Formas amorfas y polimorficas de sodio de telmisartan.
MX2007005222A (es) 2004-12-01 2007-06-26 Teva Gyogyszergyar Zartkoruen Pimecrolimus amorfo no higroscopico y en polvo.
WO2006079921A2 (en) 2005-01-28 2006-08-03 Pfizer Products Inc. Drying of drug-containing particles
KR20090015186A (ko) 2005-07-05 2009-02-11 테바 파마슈티컬 인더스트리즈 리미티드 몬테루카스트의 정제
WO2007059325A2 (en) * 2005-11-16 2007-05-24 Teva Pharmaceutical Industries Ltd. Drying methods of montelukast sodium by azeotropic removal of the solvent
GB0613925D0 (en) 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
WO2008012617A1 (en) 2006-07-21 2008-01-31 Pfizer Products Inc. Drying of drug-containing particles
GB2441328A (en) * 2006-08-30 2008-03-05 Alpharma Aps A method for obtaining mupirocin calcium
US20080187684A1 (en) * 2007-02-07 2008-08-07 Imra America, Inc. Method for depositing crystalline titania nanoparticles and films
US20090234125A1 (en) * 2007-11-26 2009-09-17 Eli Lancry Amorphous retapamulin and processes for preparation thereof
GB2457452B (en) * 2008-02-12 2010-05-12 Pliva Lachema As Amorphous form of (OC-6-43)-bis(acetate)(1-tricyclo[3,3,1,13,7]decylamine) amminedichloroplatinum (IV)
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
WO2011121596A2 (en) * 2010-04-01 2011-10-06 Neuland Laboratories Ltd. Crystal modification of moxifloxacin hydrochloride
US8471030B2 (en) 2010-12-06 2013-06-25 Orochem Technologies Inc. Purification of montelukast using simulated moving bed
WO2020049505A1 (en) 2018-09-06 2020-03-12 Innopharmascreen Inc. Methods and compositions for treatment of asthma or parkinson's disease
WO2025146702A1 (en) * 2024-01-03 2025-07-10 Msn Laboratories Private Limited, R&D Center Solid state forms of 1-{(2s,5r)-2-methyl-5-[(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino] piperidine-1-yl}prop-2-en-1-one 4-methylbenzene-1-sulfonic acid

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1643240A1 (de) 1966-09-16 1971-06-24 Boehringer Sohn Ingelheim Verfahren zur Herstellung neuer racemischer oder optisch aktiver 1-Phenoxy-2-aminoalkane
US4071536A (en) 1971-06-12 1978-01-31 Beecham Group Limited Antibiotics
GB1395907A (en) 1971-06-12 1975-05-29 Beecham Group Ltd Antibiotics
US3977943A (en) 1971-06-12 1976-08-31 Beecham Group Limited Antibiotics
JPS5270083A (en) 1975-12-04 1977-06-10 Yoshitomi Pharmaceut Ind Ltd Manufacture of an antibiotics, trans-pseudomonic acid
GB1577730A (en) 1976-10-23 1980-10-29 Beecham Group Ltd Treatment of infections with pseudomonicacid salts or esters thereof
GB1577545A (en) 1977-07-27 1980-10-22 Beecham Group Ltd Treatment of swine dysenter
CA1103264A (en) 1977-09-30 1981-06-16 Norman H. Rogers Purification of pseudomonic acid
CA1115699A (en) 1978-05-20 1982-01-05 Alan D. Curzons Lithium pseudomonate and its preparation
CA1196284A (en) 1982-05-28 1985-11-05 Joshua Oduro-Yeboah Pharmaceutical formulations
GB8415579D0 (en) 1984-06-19 1984-07-25 Beecham Group Plc Compounds
GB8428952D0 (en) 1984-11-16 1984-12-27 Beecham Group Plc Formulations
GB8530796D0 (en) 1985-12-13 1986-01-22 Beecham Group Plc Pharmaceutical composition
IE59628B1 (en) 1986-06-26 1994-03-09 Beecham Group Plc Treatment of fungal infections
US5594026A (en) 1990-12-11 1997-01-14 Smithkline Beecham Group P.L.C. Polymorphs of crystalline mupirocin
US5292892A (en) 1991-05-07 1994-03-08 Sankyo Company, Limited Anti-bacterial compound and pharmaceutical compositions thereof
US6503881B2 (en) 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
IL129237A0 (en) 1996-10-01 2000-02-17 Smithkline Beecham Corp Use of mupirocin for the manufacture of a medicament for the treatment of bacterial infections associated with colonisation of the nasopharynx by pathogenic organisms
AU5459698A (en) * 1997-11-26 1999-06-15 Universal Preservation Technologies, Inc. Preservation of sensitive biological samples by vitrification
US6231875B1 (en) 1998-03-31 2001-05-15 Johnson & Johnson Consumer Companies, Inc. Acidified composition for topical treatment of nail and skin conditions
US6306345B1 (en) 1998-05-06 2001-10-23 Universal Preservation Technologies, Inc. Industrial scale barrier technology for preservation of sensitive biological materials at ambient temperatures
PL358615A1 (en) 1999-02-03 2004-08-09 Biogal Gyogyszergyar Rt Process for the preparation of pseudomonic acid a antibiotic by microbiological method
AU771214B2 (en) 1999-02-03 2004-03-18 Teva Gyogyszergyar Reszvenytarsasag Process for the isolation of pseudomonic acid a from pseudomonic acid complex-containing culture broth
IN191492B (da) 1999-05-25 2003-12-06 Ranbaxy Lab Ltd
US6335023B1 (en) 1999-06-30 2002-01-01 Ruey J. Yu Oligosaccharide aldonic acids and their topical use
US6528086B2 (en) 1999-09-28 2003-03-04 Zars, Inc. Methods and apparatus for drug delivery involving phase changing formulations
IL137363A (en) 2000-07-18 2005-12-18 Agis Ind 1983 Ltd Pharmaceutical compositions containing mupirocin
CZ200467A3 (cs) 2001-06-21 2004-10-13 Biogalágyogyszergyarárt Metabolicky řízený způsob fermentace pro výrobu pseudomonové kyseliny
ATE440938T1 (de) 2001-07-11 2009-09-15 Procter & Gamble Verfahren zur oberflächenreinigung mittels eines dispergierten polymers
EP1455769A4 (en) 2001-12-28 2004-09-22 Biogal Gyogyszergyar METHOD FOR PRODUCING CRYSTALLINE AND AMORPHIC MUPIROCIN CALCIUM
PT1469833T (pt) 2002-02-01 2021-07-13 Bend Res Inc Método para produzir dispersões de fármaco amorfo sólido seco por pulverização homogéneas utilizando aparelho de secagem por pulverização modificado
EP1469830A2 (en) 2002-02-01 2004-10-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
IL150907A (en) 2002-07-25 2007-07-04 Stephan Cherkez Process for the preparation of stable amorphous calcium pseudomonate
MX2007005222A (es) 2004-12-01 2007-06-26 Teva Gyogyszergyar Zartkoruen Pimecrolimus amorfo no higroscopico y en polvo.

Also Published As

Publication number Publication date
IL179719A0 (en) 2007-05-15
MXPA06010084A (es) 2007-03-01
ES2339682T3 (es) 2010-05-24
WO2005117837A1 (en) 2005-12-15
US7589128B2 (en) 2009-09-15
CA2560984A1 (en) 2005-12-15
DE602005019509D1 (de) 2010-04-08
KR20060123772A (ko) 2006-12-04
US20050272768A1 (en) 2005-12-08
JP2008500405A (ja) 2008-01-10
ATE458476T1 (de) 2010-03-15

Similar Documents

Publication Publication Date Title
DK1641438T3 (da) Fremgangsmåde til fremstilling af den amorfe form af et lægemiddel
FI7617U1 (fi) Amorfisen aktiivisen ainesosan stabiloitu farmaseuttinen valmiste
EA201200937A1 (ru) Твердая лекарственная форма тикагрелора
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
NO20073959L (no) Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
CY1113462T1 (el) Μορφη δοσολογιας περιεχουσα παντοπραζολη ως δραστικο συστατικο
NO20074295L (no) Substituerte gamma lactamer som terapeutiske midler
BRPI0514738A (pt) derivados de amida de 3-fenil-diidropirimido[4,5-d]pirimidinonas, sua fabricação e aplicação como agentes farmacêuticos
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
WO2005089718A3 (en) Pharmaceutical compositions
SE0401342D0 (sv) Therapeutic compounds
DE602005007339D1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
DK1511489T3 (da) Nye farmaceutiske sammensætninger indeholdende flibanserin-polymorf A
NO20071798L (no) Dermalt pafore formuleringer for behandling av hudsykdommer i dyr
NO20071806L (no) Tabletter med steds- og tidsregulert gastrointestinal frigivelse av aktiv bestanddel.
MXPA06011467A (es) Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid).
SE0401655D0 (sv) New compounds
EA200870223A1 (ru) Производные бензоизоиндола для лечения боли
IL195062A0 (en) Process for the preparation of solid sterile active pharmaceutical ingredient
EA200602154A1 (ru) Пиридин-4-илэтинилимидазолы и -пиразолы как антагонисты рецептора mglu5
DK1617827T3 (da) Farmaceutisk sammensætning i form af en hydrogel til den transdermale administration af aktivstoffer
AR048672A1 (es) Tabletas de desintegracion que comprenden licarbazepina
TR200601092T1 (tr) İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.
IS7383A (is) Skammtaform með stýrða lyflosun til inngjafar